19:20 , May 1, 2018 |  BC Extra  |  Company News

EC approves BioCryst's Alpivab for influenza

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said the European Commission approved an MAA for Alpivab peramivir to treat uncomplicated influenza in patients at least two years old. The injectable formulation of a viral neuraminidase inhibitor is approved...
22:43 , Mar 1, 2018 |  BC Week In Review  |  Clinical News

CHMP backs approval of BioCryst's Alpivab

EMA's CHMP recommended approval of Alpivab peramivir from BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to treat uncomplicated influenza. The injectable formulation of viral neuraminidase inhibitor is approved in the U.S. as Rapivab. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham,...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Trapping influenza neuraminidase

Researchers at The University of British Columbia have used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase that could have activity against flu strains resistant to marketed inhibitors of the target. 1...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Influenza virus neuraminidase In vitro, cell culture and mouse studies suggest covalent neuraminidase inhibitors could be useful for treating influenza infection. In...
07:00 , Sep 7, 1999 |  BioCentury  |  Tools & Techniques

Why Relenza was approved

A recent FDA memorandum provides insight into the agency's thinking when it approved Biota Holdings Ltd. 's Relenza zanamivir dry powder for inhalation to treat influenza A and B - despite a 14-4 advisory committee...